If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 11 - 20 of 292
A Phase 2 Study of Cabozantinib in Combination with Atezolizumab as Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer (ABATE)
The purpose of this study is to see if the combination of Cabozantinib and Atezolizumab can
increase the chances of keeping you cancer free. Researchers will also look at the good and
bad effects of the combination including side effects.
increase the chances of keeping you cancer free. Researchers will also look at the good and
bad effects of the combination including side effects.
Protocol No
HCRN-GU18-343-ABATE
Categories
A Phase 2, Single-Arm Open-Label Study of Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration
Protocol No
IIT-CHARLSON-BOAST
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations with Organ Specific Toxicity Analysis (Re-DIRICT)
A Phase II study of Re-Irradiation Utilizing DIR and OAR Dose Calculations with Organ Specific Toxicity Analysis
Protocol No
IIT-GORE-REDIRICT
Categories
Cancer,
Colorectal,
Thoracic Cancers,
Sarcoma,
Skin Cancers,
Prostate and Urologic Cancers,
Head and Neck Cancers,
Gynecologic Cancers,
Gastrointestinal Cancers,
Endocrine Cancers,
Breast Cancers,
Brain and Spine Cancers,
Other Respiratory,
Lung,
Esophagus,
Other Skin,
Melanoma, Skin,
Other Urologic,
Bladder,
Prostate,
Kidney,
Lip, Oral Cavity and Pharynx,
Larynx,
Other Gynecologic,
Uterine,
Ovary,
Cervix,
Other Gastrointestinal,
Stomach,
Pancreas/Liver,
Esophagus
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer with High-Risk of Cancer Recurrence (PROTECT-PANC)
Molecular Profile-related Individualized Targeted Therapy in Resected Pancreatic Cancer With High-Risk of Cancer Recurrence (PROTECT-PANC)
Protocol No
IIT-KAMGAR-PROTECT-PANC
Categories
A Phase 2b Multicenter, Randomized, Open-Label Study Comparing the Efficacy, Safety, PK, and Tolerability of VH3810109, Administered Either Intravenously Or As A Subcutaneous Infusion with rHuPH20, in Combination with CAB LA to Standard of Care in Vi
HIV Embrace
Protocol No
INF-GSK-EMBRACE-HIV
Categories
Phase II Trial to Determine Role of Nodal Radiation Therapy after Sentinel Lymph Node Biopsy (SLNB) for Patients with High-Risk Sentinel Lymph Node Positive Melanoma Who Are Planned for Immunotherapy without Completion of Lymph Node Dissection (MelPO
The role of nodal radiation therapy in sentinel lymph node positive melanoma
Protocol No
MDA-2020-0148
Categories
A Long-Term, Prospective, Observational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT)
Registry of Patients with AQP4+ NMOSD Treated with Alexion C5 Inhibitor Therapies
Protocol No
NEURO-ALEXION-ALX-NMO-501
A Randomized, Double-blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lenrispodun as Adjunctive Therapy in the Treatment of Patients with Motor Fluctuations due to Parkinson's Disease
Lenrispodun Adjunctive Therapy in Parkinsons Disease
Protocol No
NEURO-ITI-214-202-LENRISPODUN
NRG-Gy031: A Phase Ib Study Of Combination Atr (M1774) And Bet Inhibition (Zen003694) To Exploit Arid1a Loss In Recurrent Ovarian And Endometrial Cancer
This phase Ib trial tests the safety, side effects, and best dose of M1774 when given with ZEN-3694 in treating patients with ovarian and endometrial cancer that has come back (recurrent). M1774 and ZEN-3694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. M1774 and ZEN-3694 combined together has demonstrated to be better than either drug alone in killing ovarian tumor cells.
Protocol No
NRG-GY031
Categories
Phase III Prospective Randomized Trial Of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed By Concurrent Mediastinal Chemoradiation For Locally Advanced Non-Small Cell Lung Cancer
Testing the addition of high dose, targeted radiation to the usual treatment for locally advanced inoperable non-small cell lung cancer
Protocol No
NRG-LU008
Categories